{"entity":{"id":"nct06479356","kind":"trial","name":"CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma","aka":[],"tldr":"A phase 2 trial of Relmacabtagene autoleucel in hodgkin lymphoma and non-hodgkin lymphoma, run by Shanghai Ming Ju Biotechnology Co., Ltd., now recruiting.","summary":"CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma is a phase 2 interventional study registered as NCT06479356 by Shanghai Ming Ju Biotechnology Co., Ltd., with 12 participants planned, started 2024-08-15 and due to reach its primary completion in 2025-04-30. Interventions recorded: Relma-cel. Conditions listed: Non-Hodgkin Lymphoma, Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06479356","url":"https://clinicaltrials.gov/study/NCT06479356"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":["relmacabtagene-autoleucel"],"companies":["jw-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06479356","phase":"2","setting":"An Open-Label, Single-Arm Study of Relma-cel, CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for Relapsed or Refractory (R/R) LBCL","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","participation":[{"nct":"NCT06479356","source":"https://clinicaltrials.gov/study/NCT06479356","fetchedAt":"2026-10-07T16:54:43.174Z","studySha256":"b5adf98eb29285c029f2f21ea3f0a26dcec2f2b28b197e474e9aafeec649490c","overallStatus":"RECRUITING","lastUpdatePosted":"2024-08-21","leadSponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":12,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2024-08-15","startedType":"actual","enrolled":12,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06479356/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"drug":[{"id":"relmacabtagene-autoleucel","kind":"drug","name":"Relmacabtagene autoleucel","route":"/drugs/relmacabtagene-autoleucel/"}],"company":[{"id":"jw-therapeutics","kind":"company","name":"JW Therapeutics","route":"/companies/jw-therapeutics/"}]}}